Swiss stocks - Factors to watch on October 26

By Reuters News

- Here are some of the main factors that may affect Swiss stocks on Monday:

COMPANY STATEMENTS


ROCHE HOLDING AG ROPC.S

The company said on Sunday its experimental lung cancer drug divarasib reduced the risk of death by 44% compared with existing treatments in a phase III study.


UBS GROUP AG UBSG.S

As many as 12,000 UBS jobs in Switzerland could be at risk if tougher capital rules prompt the bank to relocate, according to the Swiss Bank Employees Association, or SBPV.


CHOCOLADEFABRIKEN LINDT & SPRUENGLI AG LISN.S

The company has struggled because it misjudged how consumers would respond to price increases, the chair of the Swiss chocolate maker said, days after the company ousted its CEO over concerns about its performance.


NOVARTIS AG NOVN.S

Swiss drugmaker Novartis' oral multiple sclerosis (MS) drug remibrutinib meaningfully reduced relapses in patients, according to data presented at a medical conference in Toronto on Friday, but less than analysts had expected.


ROCHE HOLDING AG ROPC.S

The company presented Interim Phase Iii Data showing Sefaxersen significantly reduced proteinuria in people with Iga Nephropathy (Igan).

ECONOMY

SNB sight deposits due at 0900 GMT.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.